130 related articles for article (PubMed ID: 3774624)
21. [Biotransformation and pharmacokinetics of beta-methyl-(1,1'-biphenyl)-4-propanenitrile (LU 20884) in rats. Studies on pharmacokinetics].
Neidlein R; Hofmann G
Arzneimittelforschung; 1983; 33(8):1152-5. PubMed ID: 6685492
[TBL] [Abstract][Full Text] [Related]
22. [Ambroxol, comparative studies of pharmacokinetics and biotransformation in rat, rabbit, dog and man (author's transl)].
Hammer R; Bozler G; Jauch R; Koss FW; Hadamovsky H
Arzneimittelforschung; 1978; 28(5a):899-903. PubMed ID: 581988
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (MDL-899) in the rat and the dog.
Assandri A; Bellasio E; Bernareggi A; Cristina T; Perazzi A; Odasso G
Arzneimittelforschung; 1985; 35(2):508-13. PubMed ID: 3855234
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
Paulson SK; Zhang JY; Breau AP; Hribar JD; Liu NW; Jessen SM; Lawal YM; Cogburn JN; Gresk CJ; Markos CS; Maziasz TJ; Schoenhard GL; Burton EG
Drug Metab Dispos; 2000 May; 28(5):514-21. PubMed ID: 10772629
[TBL] [Abstract][Full Text] [Related]
25. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
26. [Human positron emission tomography with oral 11C-vinpocetine].
Vas A; Christer H; Sóvágó J; Johan S; Cselényi Z; Kiss B; Kárpáti E; Lars F; Gulyás B
Orv Hetil; 2003 Nov; 144(46):2271-6. PubMed ID: 14702922
[TBL] [Abstract][Full Text] [Related]
27. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine.
Szakács T; Veres Z; Vereczkey L
Pol J Pharmacol; 2001; 53(6):623-8. PubMed ID: 11985336
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
30. Biotransformation and pharmacokinetics of the nitrate trans-2-amino-2-methyl-N-(4-nitroxycyclohexyl)-propionamide in dogs.
Pressmar F; Neidlein R; Strein K
Arzneimittelforschung; 1992 Nov; 42(11):1306-11. PubMed ID: 1492842
[TBL] [Abstract][Full Text] [Related]
31. Preliminary pharmacokinetics of the new antitussive compound vadocaine hydrochloride in animals.
Mäntylä R; Männistö PT; Vuorela A; Nissinen E
Arzneimittelforschung; 1988 Apr; 38(4A):624-7. PubMed ID: 3395399
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog].
Obermeier K; Niebch G; Thiemer K
Arzneimittelforschung; 1985; 35(1):60-7. PubMed ID: 4039153
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics of AR-L 115 BS in rhesus monkeys (author's transl)].
Mierau J
Arzneimittelforschung; 1981; 31(1a):221-5. PubMed ID: 7195226
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 1st communication: absorption, distribution and excretion after single administration of 14C-labeled compound to rats and dogs.
Nakamura A; Sugihara K; Hirota T; Morino A; Ezumi Y; Takaichi M
Arzneimittelforschung; 1997 Feb; 47(2):151-9. PubMed ID: 9079234
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
[TBL] [Abstract][Full Text] [Related]
36. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
37. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetic studies of 14C-labeled epervudine in rats].
Dereszlay I; Vereczkey L
Acta Pharm Hung; 1993 Jul; 63(4):222-6. PubMed ID: 8379338
[TBL] [Abstract][Full Text] [Related]
39. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
[TBL] [Abstract][Full Text] [Related]
40. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.
Vickers S; Duncan CA; Arison BH; Davies RO; Ferguson R; Zacchei AG
Drug Metab Dispos; 1980; 8(3):163-7. PubMed ID: 6104580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
